To evaluate BRCA1-2 (breast cancer) detection in men with high risk PCa, including the oncological consequences for the patient and family members. From January 2023 to December 2024, 52 men (median age 73 years;) with confirmed PCa diagnosis underwent …

Video content above is prompted by the following: Emerging Genomic Testing Advances: Clinical Implications for the Next 5 Years Key Projected Developments Precision Personalized Medicine Genomic testing is expected to become increasingly sophisticated in …

… with a family history of hereditary diseases. Immunohistochemistry (IHC) Briefly, … in patients with prostate cancer (Figure 1). Patients with prostate cancer showed positive … Qi Y, et al. Reshaping prostate tumor microenvironment to suppress metastasis via …

Prostate Cancer (PrCa) is one of the … of the disease when diagnosed. Hereditary cancer in clinical practice. 2025 …

… breast cancer, metastatic prostate cancer, and pheochromocytomas. Just … cancer, or metastatic prostate cancer? There’s a … breast cancer, metastatic prostate cancer, and—the one … testing for hereditary breast, ovarian, pancreatic, and prostate cancers. National …

… -causing variants associated with hereditary cancer syndromes across organ … due to backlogs in hereditary cancer screening. Our solution … age of 50, metastatic prostate cancer or male breast cancer. … risk of a specific hereditary cancer syndrome and having …

… of the risk attributable to hereditary elements and age. This information … cancer statisticsglobal prostate cancer prevalencelow-risk prostate cancer treatment optionsoncologist insights on prostate cancerpatient education on …

… later. Our family history of hereditary cancer seemed to have stemmed … , Larry’s dad, suffered from prostate cancer in the early 2000s, in … cancer. Later, Larry fought off prostate cancer. Years past, and in the …

… as well as genetic and hereditary risks in the patient. … multiple proteomic, transcriptomic, genetic/hereditary and epigenetic biomarker signatures which … into routine screening could revolutionise prostate cancer management by enabling earlier detection …

… , and what the genetic or hereditary risks for a patient may … test measures 100 clinically validated prostate cancer biomarkers, the most currently known … multiple proteomic, transcriptomic, genetic/hereditary, and epigenetic biomarker signatures, with …